Table 3 Infections and immunosuppression in EAD versus non-EAD patients
Whole cohort (n = 231) | Study cohort (n = 110) | Non-EAD (n = 62) | EAD (n = 48) | p-value | |
|---|---|---|---|---|---|
Preoperative State | |||||
Recipient status | 0.120 | ||||
At home | 158 (68.4%) | 67 (60.9%) | 34 (54.8%) | 33 (68.8%) | |
Admission general ward | 42 (18.2%) | 21 (19.1%) | 16 (25.8%) | 5 (10.4%) | |
Admission on ICU | 31 (13.4%) | 22 (20%) | 12 (19.4%) | 10 (20.8%) | |
Preoperative infection* | 39 (16.%) | 20 (18.2%) | 13 (21.0%) | 7 (14.6%) | 0.389 |
Laboratory inflammatory parameters | |||||
CRP (mg/l) (n = 109) | 8.7 (3.0–22.0) | 10 (4.1–24.0) | 15 (3.8–28.5) | 7.6 (4.2–16.8) | 0.142 |
PCT (mcg/l) (n = 20) | 1.1 (0.7–2.3) | 1.2 (0.7–2.1) | 1.4 (0.8–1.8) | 1.0 (0.6–2.7) | 0.656 |
WBC (G/l) | 5.3 (3.7–7.0) | 5.5 (3.9–7.4) | 5.7 (4.5–7.5) | 5.3 (3.3–7.4) | 0.258 |
Postoperative infections | |||||
Infection in first week | 35 (15.2%) | 21 (19.1%) | 11 (17.7%) | 10 (20.8%) | 0.682 |
Donor transmitted Infection | 5 (2.2%) | 4 (3.6%) | 2 (3.2%) | 2 (4.2%) | |
Respiratory tract infection | 5 (2.2%) | 2 (1.8%) | 1 (1.6%) | 1 (2.1%) | |
Intraabdominal infection | 8 (3.5%) | 4 (3.6%) | 2 (3.2%) | 2 (4.2%) | |
Urogenital infection | 4 (1.7%) | 3 (2.7%) | 1 (1.6%) | 2 (4.2%) | |
Blood stream infection | 2 (0.9%) | 1 (0.9%) | 1 (1.6%) | 0 | |
Viral infection | 3 (1.3%) | 2 (1.8%) | 1 (1.6%) | 1 (2.1%) | |
Other infection | 12 (5.2%) | 5 (4.5%) | 3 (4.8%) | 2 (4.2%) | |
Immunosuppression and rejection | |||||
Tacrolimus | 222 (96.1%) | 105 (95.5%) | 61 (98.4%) | 44 (91.7%) | 0.093 |
Basiliximab | 167 (72.3%) | 81 (73.6%) | 45 (72.6%) | 36 (75.0%) | 0.775 |
Acute rejection in first week | 3 (1.3%) | 2 (1.8%) | 0 | 2 (4.2%) | 0.188 |